Netherlands Discussion Group
Short Course: Characterization of Biopharmaceuticals | 24 October 2024
Instructors
Pepijn Burgers, Johnson & Johnson Innovative Medicine
Eef Dirksen, Byondis B.V.
Karin Hoogendoorn, Galapagos NV
This Netherlands Area Biotech (NLab) Discussion Group short course addresses the different aspects that are relevant for the extended characterization of biopharmaceutical products according to regulatory guidelines and expectations. It is intended for both junior and experienced analytical and regulatory staff that work in the field of CMC development of biopharmaceuticals, from either an industry, academic, or regulatory point of view.
The CMC Strategy Forum Europe will take place on 21-23 October 2024 and precedes the Short Course on 24 October 2024. We encourage attendees to register for both the Forum and Short Course. (Note: Separate registration fees apply for the Forum)
The course will be held on Thursday, 24 October 2024. Your course registration includes this full-day course which is scheduled from 9:30 - 17:30 CET, lunch, as well as any supplemental presentation materials that will be provided during the session.
Registration Fees
| Regular by 4 OCTOBER 2024* | $635.00 |
| ONSITE** | $735.00 |
Location
DoubleTree by Hilton Rotterdam Centre (formerly MaasHotel Rotterdam Centre and Mainport Hotel Rotterdam)
Leuvehaven 80
Rotterdam, Zuid-Holland 3011 EA, Netherlands
Telephone: +31 413 4139
Instructors
Pepijn Burgers, Johnson & Johnson Innovative Medicine
Eef Dirksen, Byondis B.V.
Karin Hoogendoorn, Galapagos NV
This Netherlands Area Biotech (NLab) Discussion Group short course addresses the different aspects that are relevant for the extended characterization of biopharmaceutical products according to regulatory guidelines and expectations. It is intended for both junior and experienced analytical and regulatory staff that work in the field of CMC development of biopharmaceuticals, from either an industry, academic, or regulatory point of view.
Different critical quality attributes (CQA) categories, e.g., potency, product related impurities and process related impurities, should be monitored extensively as these impact quality, safety and/or efficacy of biopharmaceuticals such as monoclonal antibody-based products, (viral) vectors, and cell therapy products. Analytical characterization data is used to understand the various CQA categories throughout the lifecycle of the product as part of process and product characterization. This data can further support comparability studies, investigations, reference material qualifications, et cetera.
In this course, we aim to provide insight into analytical characterization and show how analytical characterization data can be acquired systematically to eventually find its way into the various sections of Module 3 of regulatory submission filings. The course will cover the following:
- Defining a characterization strategy
- The advanced analytical technologies available for characterization
- How characterization can support determination of critical quality attributes
- Different purposes of product characterization, e.g., comparability and reference material qualifications
- Current regulatory guidelines
- Interactions with regulatory authorities (scientific advice, clinical trial application, commercial license application, e.g., BLA)
- Expectations at different phases of clinical development and commercial stage
We will provide a solid theoretical background on the analytical methods that are typically used to thoroughly characterize complex biotherapeutic molecules, not only biochemically, but also biophysically and biologically. In addition, an overview will be presented on the structure of Module 3 and what sections typically contain analytical characterization data to demonstrate sufficient knowledge on, e.g. the molecular structure, the most common degradation pathways of the biotherapeutic and how these impact the functionality of the product. Moreover, the course will feature case studies that focus on specific applications of characterization strategies to gain insight into the molecular heterogeneity of biotherapeutic products.
The course is intended for both junior and experienced analytical and regulatory staff that work in the field of CMC development of biopharmaceuticals, from either an industry, academic, or regulatory point of view. It is also valuable for people working in adjacent fields such as research, quality control/assurance, or process development.
Promote Your Participation
Here are some ways you can share your message:
- Follow CASSS on Facebook, X, and LinkedIn. Stay up-to-date on the latest Discussion Group announcements and opportunities. Links can be found in the right column or at the bottom of this page.
- Share your participation via your personal Facebook, Twitter, and LinkedIn accounts. Whether you are a recurring presenter or this is your first time attending, we are grateful to have you join us this year.
- Share the news with your colleagues who run your organization's official social media channels. We are proud to show our community your participation - let your community convey their support too.
- Join our CASSS LinkedIn Group to help create additional discussion before the Discussion Group and beyond about topics of interest with like-minded people. https://www.linkedin.com/groups/2361040/
- Personalize your email signature. Add an image or short message to your default email signature to let your colleagues know you will be attending the Discussion Group.
- Remember to tag CASSS and use #NLab2024 on all social media posts.
If you have any questions about this media kit, please reach out to Renee Olson.
*All registration fees are in US dollars. 21% VAT will be added at checkout. Local VAT must be charged in accordance with Dutch law based on where the conference/exhibition is taking place. Short Course participants are able to reclaim VAT, if they qualify. Additional information will be provided with your VAT invoice.
**Onsite registration is subject to availability and is not guaranteed.
Cancellation Policy
A refund will be available if cancellation notice is received in the CASSS office by Friday, 4 October 2024, less an administrative
fee equal to 10% of the registration fee (in US dollars). No refunds will be available after this date. Substitutions are accepted.
CASSS is a non-profit professional membership society that provides networking and peer-to-peer learning opportunities for professionals involved in the development and regulation of biopharmaceutical products worldwide.
Contributions or gifts to CASSS are not tax deductible as charitable contributions; however, they may be tax deductible as ordinary and necessary business expenses. Please consult your tax advisor. The CASSS Federal Tax ID number is 77-0048350.
